Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2010 2
2011 2
2012 2
2013 3
2014 1
2015 5
2016 9
2017 17
2018 9
2019 11
2020 5
2021 8
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

69 results
Results by year
Filters applied: . Clear all
Page 1
Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L. Allard B, et al. Among authors: aspeslagh s. Semin Cancer Biol. 2018 Oct;52(Pt 2):1-11. doi: 10.1016/j.semcancer.2018.02.005. Epub 2018 Feb 8. Semin Cancer Biol. 2018. PMID: 29428479 Review.
Cancer immunotherapy-associated hypophysitis.
Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S, Saba L. Solinas C, et al. Among authors: aspeslagh s. Semin Oncol. 2018 Jun;45(3):181-186. doi: 10.1053/j.seminoncol.2018.09.002. Epub 2018 Oct 21. Semin Oncol. 2018. PMID: 30352754 Review.
PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.
Tuyaerts S, Van Nuffel AMT, Naert E, Van Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, Amant F, Vandecasteele K, Denys H. Tuyaerts S, et al. Among authors: aspeslagh s. BMC Cancer. 2019 May 28;19(1):506. doi: 10.1186/s12885-019-5676-3. BMC Cancer. 2019. PMID: 31138229 Free PMC article. Clinical Trial.
Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. Aspeslagh S, et al. Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30. Eur J Cancer. 2016. PMID: 26645943 Review.
Are phase I trials safe for older patients?
Baldini C, Le Saux O, Helissey C, Aspeslagh S, Castanon E, Varga A, Gazzah A, Bahleda R, Mir O, Massard C, Soria JC, Hollebecque A. Baldini C, et al. Among authors: aspeslagh s. J Geriatr Oncol. 2018 Mar;9(2):87-92. doi: 10.1016/j.jgo.2017.08.012. Epub 2017 Sep 8. J Geriatr Oncol. 2018. PMID: 28890328 Review.
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, Martínez-Vila C, Wallace R, Bhave P, Reijers ILM, Thompson N, Vanella V, Gerard CL, Aspeslagh S, Labianca A, Khattak A, Mandala M, Xu W, Neyns B, Michielin O, Blank CU, Welsh SJ, Haydon A, Sandhu S, Mangana J, McQuade JL, Ascierto PA, Zimmer L, Johnson DB, Arance A, Lorigan P, Lebbé C, Carlino MS, Sullivan RJ, Long GV, Menzies AM. Owen CN, et al. Among authors: aspeslagh s. Ann Oncol. 2021 Jul;32(7):917-925. doi: 10.1016/j.annonc.2021.03.204. Epub 2021 Mar 30. Ann Oncol. 2021. PMID: 33798657 Free article.
Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S. Michot JM, et al. Among authors: aspeslagh s. Eur J Cancer. 2017 Nov;85:67-77. doi: 10.1016/j.ejca.2017.08.014. Epub 2017 Sep 9. Eur J Cancer. 2017. PMID: 28892775 Review.
69 results